
Hyperglycemia: A Risky Side Effect of Certain Cancer Drugs
The October 2024 approval of inavolisib for advanced breast cancer spotlighted a growing problem in breast oncology: Managing the hyperglycemia caused by phosphoinositide 3-kinase (PI3K)/Akt pathway inhibitors. Inavolisib is one of a growing class of …